EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Topical Sanshool‐Derived Formulations for Melasma: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Weiyi Xiang, Xinjin Liu, Tianyou Wang, Zhipeng Gu, Linghong Guo, Xian Jiang

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/8731967 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 08.07.2026. Verfasst von Weiyi Xiang und 5 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melasma is a chronic hyperpigmentary disorder with frequent relapse and limited treatment satisfaction. Hydroxy‐α‐sanshool and its derivatives have shown potential in ameliorating photodamage, suggesting possible therapeutic value in melasma.

Objective

To evaluate the efficacy and safety of topical sanshool and its derivatives in patients with melasma.

Methods

In this randomized, double‐blind, placebo‐controlled clinical trial, 68 patients with melasma were assigned to four groups receiving pure sanshool (S), melanin‐sanshool (MS), polyphenol‐sanshool (PS), or placebo vehicle (NA) once nightly for 12 weeks. Melasma Area and Severity Index (MASI), skin luminance (L‐value), and melanin index (MI) were assessed at baseline and at weeks 4, 8, and 12.

Results

At Week 12, all three sanshool‐derived formulations demonstrated significant clinical benefit over placebo. MASI score reductions were −0.87 ± 0.15 (S), −1.18 ± 0.15 (MS), and −0.80 ± 0.15 (PS), versus −0.01 ± 0.17 in the placebo group ( p < 0.001). L‐value increased by 0.48 ± 1.05 (S), 0.91 ± 1.14 (MS), and 1.06 ± 0.95 (PS), compared with a slight decrease of −0.23 ± 1.03 in placebo ( p = 0.005). MI decreased by −2.52 ± 10.91 (S), −7.47 ± 11.68 (MS), and −5.18 ± 11.08 (PS), versus an increase of 8.86 ± 18.95 in placebo ( p = 0.009), showing concordant improvements in MASI, skin luminance, and MI. Notably, PS showed the strongest brightening effect ( p < 0.001), whereas MS achieved the greatest reduction in pigmentation ( p = 0.04). All treatments were well tolerated, and no serious adverse events were observed.

Conclusion

Topical sanshool‐derived formulations significantly improved clinical severity, skin luminance, and pigmentation parameters in patients with melasma compared with placebo. MS and PS formulations showed enhanced effects on selected pigmentation‐related outcomes. These findings support the therapeutic potential of sanshool‐derived formulations as topical agents for pigmentary skin disorders. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2300077100

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Xiang, W., Liu, X., Wang, T., Gu, Z., Guo, L., & Jiang, X. (2026). Efficacy and Safety of Topical Sanshool‐Derived Formulations for Melasma: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/8731967

Vancouver

Xiang W, Liu X, Wang T, Gu Z, Guo L, Jiang X. Efficacy and Safety of Topical Sanshool‐Derived Formulations for Melasma: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/8731967

BibTeX
@article{Xiang2026,
  author = {Xiang, Weiyi and Liu, Xinjin and Wang, Tianyou and Gu, Zhipeng and Guo, Linghong and Jiang, Xian},
  title = {Efficacy and Safety of Topical Sanshool‐Derived Formulations for Melasma: A Randomized, Double‐Blind, Placebo‐Controlled Trial},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/8731967}
}
Kostenlos starten →